{"id":"NCT02292446","sponsor":"Novartis Pharmaceuticals","briefTitle":"Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.","officialTitle":"An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-21","primaryCompletion":"2017-12-29","completion":"2017-12-29","firstPosted":"2014-11-17","resultsPosted":"2019-04-02","lastUpdate":"2019-07-18"},"enrollment":161,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Polycythemia Vera"],"interventions":[{"type":"DRUG","name":"Ruxolitinib","otherNames":[]}],"arms":[{"label":"All patients","type":"EXPERIMENTAL"}],"summary":"The purpose of this open-label, single arm, multi-center Expanded Treatment Protocol (ETP) was to provide early access to ruxolitinib and evaluate safety information in patients with polycythemia vera (PV) who were hydroxyurea (HU) resistant or intolerant and who had no other standard treatment option, nor did they qualify for another clinical study for PV","primaryOutcome":{"measure":"Number of Participants With Adverse Events - All Grades","timeFrame":"Baseline up to approximately 26 months","effectByArm":[{"arm":"All Patients","deltaMin":143,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":65,"countries":["Austria","Belgium","Bulgaria","Canada","Chile","France","Germany","Mexico","Norway","Portugal","Sweden","Thailand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":161},"commonTop":["Anaemia","Headache","Diarrhoea","Constipation","Fatigue"]}}